Login to Your Account



Gurnet Point commits $600M to development-focused start-up Boston Pharmaceuticals

By Michael Fitzhugh
Staff Writer

Thursday, November 19, 2015

Just five months after former Sanofi SA chief Chris Viehbacher took charge of the $2 billion health care fund Gurnet Point Capital, he's launching a drug development venture dedicated to transforming undeveloped but promising molecules into a portfolio of high-quality, phase III-ready assets.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription